YD Bio

YD Bio FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of YD Bio (YDES) as of Oct 16, 2026 is 96.70 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 336.35 % — a change of -71.25% (lower).

FCF Conversion

96.70 %

YoY

-71.25%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of YD Bio is 2025 96.70 % . FCF Conversion Rate (FCF/EBITDA) of YD Bio was 2024 336.35 % . It decreases by -71.25% lower compared to the previous year.

The YD Bio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
9.99 USD
Jan 1, 2021
-7.91 USD
Jan 1, 2022
-79.79 USD
Jan 1, 2023
-412.59 USD
Jan 1, 2024
336.35 USD
Jan 1, 2025
96.70 USD
The YD Bio FCF Conversion history
YEARFCF ConversionYoY
96.70 %-71.25%
336.35 %-181.52%
-412.59 %+417.08%
-79.79 %+908.85%
-7.91 %-179.14%
9.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

FCF Conversion Rate (FCF/EBITDA) of YD Bio is 96.70 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of YD Bio changed from 336.35 % to 96.70 %, representing a -71.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) YD Bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s YD Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — YD Bio

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — YD Bio